Eli Lilly, the maker of Zepbound and Mounjaro, said it's experimental GLP-1 pill successfully helped adults with obesity lose ...

A daily pill that works like Ozempic can help slimmers lose an average of two stone, trials have found. The study of ...

US stocks were mixed Thursday morning as President Trump's sweeping tariffs hit dozens of US trade partners after his ...

A woman whose daughter nearly died after a liquid BBL (Brazilian butt lift) procedure says she is "disappointed and upset" ...

Vizient released its Summer 2025 Spend Management Outlook forecasting a 3.35% increase in pharmaceutical prices in 2026 with healthcare providers seeing increased usage in GLP-1 therapies, specialty ...

Results from a late-stage trial of Eli Lilly's experimental weight-loss pill were disappointing, sending shares of the ...

Live Updates Live Coverage Updates appear automatically as they are published. Discovery-ing Some Profits 9:40 am Continuing ...

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Pharmaceutical giant Eli Lilly (LLY) has reported second-quarter financial results that beat Wall Street estimates and raised ...

A trial assessing a new daily pill for weight loss has shown that people taking the drug can shed kilos in weeks, potentially ...

At the same time, Trump's hint of a carveout for coming duties on semiconductors boosted tech for a second consecutive day. The Dow Jones Industrial Average (^DJI) gained 0.6%, while the S&P 500 ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...